Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Korde

Showing results (51-60 of 125) with videos related to

Pageof 13
Sort By:
Elife|September 2, 2015
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunitsDiego Acosta-Alvear, Min Y Cho, Thomas Wild, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
The Journal of Molecular Diagnostics : JMD|October 5, 2015
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease ProgressionWeixin Wang, Meghan Corrigan-Cummins, Emily A Barber, et al.
Scientific Reports|March 2, 2021
Oncologic immunomodulatory agents in patients with cancer and COVID-19Justin Jee, Aaron J Stonestrom, Sean Devlin, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Plos One|November 2, 2018
Dietary intake is associated with risk of multiple myeloma and its precursor diseaseMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Leukemia Research|January 28, 2014
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesPrashant R Tembhare, Constance M Yuan, David Venzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Pageof 13

Showing results (51-60 of 125) with videos related to

Sort By:
Pageof 13
Elife|September 2, 2015
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunitsDiego Acosta-Alvear, Min Y Cho, Thomas Wild, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Leukemia & Lymphoma|May 10, 2017
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenanceHani Hassoun, Mikhail Roshal, Joshua Sabari, et al.
The Journal of Molecular Diagnostics : JMD|October 5, 2015
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease ProgressionWeixin Wang, Meghan Corrigan-Cummins, Emily A Barber, et al.
Scientific Reports|March 2, 2021
Oncologic immunomodulatory agents in patients with cancer and COVID-19Justin Jee, Aaron J Stonestrom, Sean Devlin, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Plos One|November 2, 2018
Dietary intake is associated with risk of multiple myeloma and its precursor diseaseMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Leukemia Research|January 28, 2014
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesPrashant R Tembhare, Constance M Yuan, David Venzon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2024
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple MyelomaDickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, et al.
Pageof 13